No Data
FDA Advisory Panel to Discuss Makeup of Updated COVID Shots
Evercore Maintains BioNTech(BNTX.US) With Buy Rating, Maintains Target Price $125
UBS Maintains BioNTech(BNTX.US) With Hold Rating, Maintains Target Price $115
Express News | Form 144 | BioNTech(BNTX.US) Director Proposes to Sell 14.21 Million in Common Stocks
Analysts Conflicted on These Healthcare Names: Immutep Ltd (OtherPRRUF), Organon (OGN) and BioNTech SE (BNTX)
Strategic Importance of BioNTech's COVID-19 Vaccine and Oncology Ambitions Drive Buy Rating